340 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Company News For Jun 20, 2019 http://www.zacks.com/stock/news/432199/company-news-for-jun-20-2019?cid=CS-ZC--432199 Jun 20, 2019 - Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data http://www.zacks.com/stock/news/431676/biotech-stock-roundup-amgen-gets-fda-nod-for-kanjinti-regeneron-presents-data?cid=CS-ZC-FT-431676 Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti http://www.zacks.com/stock/news/429548/amgen-allergan-get-fda-nod-for-herceptin-biosimilar-kanjinti?cid=CS-ZC-FT-429548 Jun 14, 2019 - FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 http://www.zacks.com/stock/news/425026/ironwood-initiates-dosing-in-mid-stage-study-for-md-7246?cid=CS-ZC-FT-425026 Jun 05, 2019 - Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression http://www.zacks.com/stock/news/421714/allergans-agn-vraylar-gets-fda-nod-for-bipolar-depression?cid=CS-ZC-FT-421714 May 29, 2019 - Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433 May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Allergan Plc (AGN) CEO Brent Saunders on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4261019-allergan-plc-agn-ceo-brent-saunders-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare May 07, 2019 - Allergan Plc (NYSE:AGN) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Manisha Narasimhan - Vice President of Investor Relations and Strategic Initiatives Brent Saunder
Allergan PLC (AGN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/07/allergan-plc-agn-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 May 07, 2019 - AGN earnings call for the period ending May 7, 2019.
Why Are Investors Passing on Teva Pharmaceutical Industries? https://www.fool.com/investing/2019/05/05/why-are-investors-passing-on-teva-pharmaceutical-i.aspx?source=iedfolrf0000001 May 05, 2019 - Teva's turnaround won't kick into high gear anytime soon.
Why the Earnings Surprise Streak Could Continue for Allergan (AGN) http://www.zacks.com/stock/news/408551/why-the-earnings-surprise-streak-could-continue-for-allergan-agn?cid=CS-ZC-FT-408551 May 03, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pages: 123456...34

Page 1>